Systematic Evaluation of Hyperspectral Analysis as a Predictive Marker of Preeclampsia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia. Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia. The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: t
View:

• singleton pregnancies

• age ≥ 18 years

• patient's ability to provide consent

• written informed consent

• women scheduled for a routine ultrasound scan in first or second trimester

Locations
Other Locations
Germany
Heidelberg University Hospital, Department of Gynecology and Obstetrics
RECRUITING
Heidelberg
Contact Information
Primary
Anna S Dr. med. Anna Scholz, MD
anna.scholz@med.uni-heidelberg.de
+49 6221 56 32080
Backup
Alexandra von Au, MD
Time Frame
Start Date: 2025-08-21
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 1430
Treatments
First trimester
patients scheduled for routine first trimester ultrasound assessment
Second trimester
patients scheduled for routine anomaly scan in second trimester
Related Therapeutic Areas
Sponsors
Leads: Heidelberg University

This content was sourced from clinicaltrials.gov